Acute myelogenous leukemia after exposure to strontium-89 for the treatment of adenocarcinoma of the prostate

Cancer

Volumn 88, Issue 3, 2000, Pages 620-624

  Kossman, Steven E ^a   Weiss, Mark A ^a,b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Acute myelogenous leukemia; Myelodysplastic syndrome; Prostate; Strontium

Indexed keywords

STRONTIUM 89;

ACUTE GRANULOCYTIC LEUKEMIA; AGED; ARTICLE; BONE MARROW SUPPRESSION; CASE REPORT; HUMAN; LEUKEMOGENESIS; MALE; MYELODYSPLASTIC SYNDROME; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; THROMBOCYTOPENIA;

EID: 0034141505     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0142(20000201)88:3<620::aid-cncr19>3.0.co;2-%23     Document Type: Article

References (33)

1. Robinson RG, Preston DF, Spicer JA, Baxter KG. Radionuclide therapy of intractable bone pain: emphasis on strontium-89. Semin Nucl Med 1992;22(1):28-32.
2. Pecher C. Biologic investigations with radioactive calcium and strontium. Preliminary report on the use of radioactive strontium in the treatment of metastatic bone cancer. Univ California Publ Pharmacol 1942;2:117-49.
3. Laing AH, Ackery DM, Bayly RJ, Buchanan RB, Lewington VJ, McEwan AJ, et al. Strontium-89 chloride for pain and palliation in prostatic skeletal malignancy. Br J Radiol 1991;64: 816-22.
4. Blake GM, Zivanovic MA, McEwan AJ, Ackery DM. Sr-89 therapy: strontium kinetics in disseminated carcinoma of the prostate. Eur J Nucl Med 1986;12:447-54.
5. Tennvall J, Darte L, Lundgren R, el Hassam AM. Palliation of multiple bony metastases from prostatic carcinoma with strontium-89. Acta Oncol 1988;27:345-8.
6. Robinson RG, Spicer JA, Preston DF, et al. Treatment of metastatic bone pain with strontium-89. Nucl Med Biol 1987;14:219-22.
7. Correns HJ, Mebel M, Buchali K, Schnorr D, Seidel C, Mitterlechner E. Strontium-89 therapy of bone metastases of carcinoma of the prostate gland. Eur J Nucl Med 1979;4: 33-5.
8. Robinson RG, Blake GM, Preston DF, McEwan AJ, Spicer JA, Martin NL, et al. Strontium-89: treatment results and kinetics in patients with painful metastatic prostate and breast cancer in bone. Radiographics 1989;9:271-81.
9. Lewington VJ, McEwan AJB, Ackery DM, Bayly RJ, Keeling DH, Macleod PM, et al. A prospective randomized double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone. Eur J Cancer 1991;27: 954-8.
10. Porter AT, McEwan AJB, Powe JE, Reid R, McGowan DG, Lukka H, et al. Results of a randomized phase-III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys 1993;25:805-13.
11. 90Sr. Health Phys 1966;12(9):1362-5.
12. 90Sr. Blood 1969;34(5):610-32.
13. Preston DL, Kusumi S, Tomonaga M, Izumi S, Ron E, Kuramoto A, et al. Cancer incidence in atomic bomb survivors. III. Leukemia, lymphoma, and multiple myeloma, 1950-1987. Radiat Res 1994;137:S68.
14. Land CE, Tokunaga M. Induction period. In: Boice JD, Fraumeni JF, editors. Radiation carcinogenesis: epidemiology and biological significance. New York: Raven Press, 1984:.
15. Ishimaru T, Otake M, Ichimaru M. Dose-response relationship of neutrons and gamma rays to leukemia incidence among atomic bomb survivors in Hiroshima and Nagasaki by type of leukemia, 1950-1971. Radiation Res 1979;77:377-94.
16. Sandler DP, Collman GW. Cytogenetic and environmental factors in the etiology of the acute leukemias in adults. Am J Epidemiol 1987;126:1017-32.
17. Sandler DP. Epidemiology and etiology of leukemia. Curr Opin Oncol 1990;2:3-9.
18. Cartwright RA. Leukaemia epidemiology and radiation risks. Blood Rev 1992;6:10-4.
19. Griem ML, Kleinerman RA, Boice JD Jr., Stovall M, Shefner D, Lubin JH. Cancer following radiotherapy for peptic ulcer. J Natl Cancer Inst 1994;86:842-9.
20. Rowley J, Golomb H, Vardiman J. Non-random chromosomal abnormalities in acute nonlymphocytic leukemia in patients treated for Hodgkin's disease and non-Hodgkin's lymphomas. Blood 1977;50:759-70.
21. Arseneau JC, Sponzo RW, Levin DL, Schnipper LE, Bonner H, Young RC, et al. Nonlymphomatous malignant tumors complicating Hodgkin's Disease. N Engl J Med 1972;287: 1119.
22. Aisenberg AC. Acute nonlymphocytic leukemia after treatment for Hodgkin's Disease. Am J Med 1983;75:449.
23. Kaldor JM, Day NE, Clark EA, Van Leeuwen EE, Henry-Amar M, Fiorentino MV, et al. Leukemia following Hodgkin's Disease. N Engl J Med 1990;322:7-13.
24. Curtis RE, Boice JD Jr., Moloney WC, Ries LG, Flannery JT. Leukemia following chemotherapy for breast cancer. Cancer Res 1990;50(9):2741-6.
25. Laughlin MJ, McGaughey DS, Crews JR, Chao NJ, Rizzieri D, Ross M, et al. Secondary myelodysplasia and acute leukemia in breast cancer patients after autologous bone marrow transplant. J Clin Oncol 1998;16(3):1008-12.
26. Prior P, Pope DJ. Subsequent primary cancers in relation to treatment of ovarian cancer. Br J Cancer 1989;59:453-9.
27. Travis LB, Curtis RE, Boice JD Jr., Platz CE, Hankey BF, Fraumeni JF Jr. Second malignant neoplasms among long-term survivors of ovarian cancer. Cancer Res 1996;56:1564-70.
28. Kyle RA, Pierre RV, Bayrd ED. Multple myeloma and acute leukemia associated with alkylating agents. Arch Intern Med 1975;135:185-92.
29. Einhorn N. Acute leukemia after chemotherapy (melphalan). Cancer 1978;41:444-7.
30. Hawkins MM. Secondary leukaemia after epipodophyllotoxins. Lancet 1991;338:1408.
31. Devore R, Whitlock J, Hainsworth JD, Johnson DH. Therapy-related acute nonlymphocytic leukemia with monocytic features and rearrangements of chromosome 11q. Ann Intern Med 1989;110:740.
32. Ratain MJ, Kaminer LS, Bitran JD, Larson RA, Le Beau MM, Skosey C, et al. Acute nonlymphocytic leukemia following etoposide and cisplatin combination chemotherapy for advanced non-small-cell carcinoma of the lung. Blood 1987; 70:1412-7.
33. Aziz H, Choi K, Sohn C, Yaes R, Rotman M. Comparison of P32 and SHBI for bony metastases. Am J Clin Oncol 1986;9: 264-8.